Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.

Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD.

Patient Prefer Adherence. 2017 Feb 23;11:305-322. doi: 10.2147/PPA.S126651. eCollection 2017. Review.

2.

Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.

Atema V, van Leeuwen M, Oldenburg HS, Retèl V, van Beurden M, Hunter MS, Aaronson NK.

BMC Cancer. 2016 Nov 25;16(1):920.

3.

Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.

Turner K, Samuel CA, Donovan HA, Beckjord E, Cardy A, Dew MA, van Londen GJ.

Support Care Cancer. 2017 Apr;25(4):1055-1061. doi: 10.1007/s00520-016-3491-9. Epub 2016 Nov 18.

4.

Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo.

Abrahamsson A, Rzepecka A, Romu T, Borga M, Leinhard OD, Lundberg P, Kihlberg J, Dabrosin C.

Oncoimmunology. 2016 Sep 2;5(10):e1229723. eCollection 2016.

PMID:
27853653
5.

Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.

Bosco-Lévy P, Jové J, Robinson P, Moore N, Fourrier-Réglat A, Bezin J.

Br J Cancer. 2016 Oct 11;115(8):912-919. doi: 10.1038/bjc.2016.276. Epub 2016 Sep 6.

PMID:
27599040
6.

Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care-Insured Women, New York State, 2012-2014.

Wagner VL, Jing W, Boscoe FP, Schymura MJ, Roohan PJ, Gesten FC.

Prev Chronic Dis. 2016 Sep 1;13:E120. doi: 10.5888/pcd13.160185.

7.

Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer.

Milata JL, Otte JL, Carpenter JS.

Cancer Nurs. 2016 Aug 18. [Epub ahead of print]

PMID:
27532743
8.

Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.

Farias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI, Thompson B.

J Manag Care Spec Pharm. 2016 Aug;22(8):969-78. doi: 10.18553/jmcp.2016.22.8.969.

9.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thürlimann B.

J Clin Oncol. 2016 Jul 20;34(21):2452-9. doi: 10.1200/JCO.2015.63.8619. Epub 2016 May 23.

PMID:
27217455
10.

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.

Wells KJ, Pan TM, Vázquez-Otero C, Ung D, Ustjanauskas AE, Muñoz D, Laronga C, Roetzheim RG, Goldenstein M, Carrizosa C, Nuhaily S, Johnson K, Norton M, Sims E, Quinn GP.

Support Care Cancer. 2016 Oct;24(10):4123-30. doi: 10.1007/s00520-016-3229-8. Epub 2016 May 5.

PMID:
27146492
11.

Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.

Walker HE, Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH.

J Adolesc Young Adult Oncol. 2016 Mar;5(1):16-23. doi: 10.1089/jayao.2015.0051. Epub 2015 Dec 17.

12.

Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer.

Bradley CJ, Dahman B, Jagsi R, Katz S, Hawley S.

Breast Cancer Res Treat. 2015 Nov;154(2):417-22. doi: 10.1007/s10549-015-3630-x. Epub 2015 Nov 9.

13.

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.

Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, den Boer TD, Lam MH, Jager A, van Gelder T, Mathijssen RH.

Clin Pharmacokinet. 2016 Feb;55(2):249-55. doi: 10.1007/s40262-015-0315-x.

14.

Oral antineoplastic agents: how do we care about adherence?

Barillet M, Prevost V, Joly F, Clarisse B.

Br J Clin Pharmacol. 2015 Dec;80(6):1289-302. doi: 10.1111/bcp.12734. Epub 2015 Oct 28. Review.

15.

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Kimmick G, Edmond SN, Bosworth HB, Peppercorn J, Marcom PK, Blackwell K, Keefe FJ, Shelby RA.

Breast. 2015 Oct;24(5):630-6. doi: 10.1016/j.breast.2015.06.010. Epub 2015 Jul 16.

16.

Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis.

Mausbach BT, Schwab RB, Irwin SA.

Breast Cancer Res Treat. 2015 Jul;152(2):239-46. doi: 10.1007/s10549-015-3471-7. Epub 2015 Jun 16. Review.

17.

The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.

Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, Smallwood AJ, Laud PW, Pezzin LE.

J Natl Cancer Inst. 2015 May 12;107(8). pii: djv130. doi: 10.1093/jnci/djv130. Print 2015 Aug.

18.

Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.

Roberts MC, Wheeler SB, Reeder-Hayes K.

Am J Public Health. 2015 Jul;105 Suppl 3:e4-e15. doi: 10.2105/AJPH.2014.302490. Epub 2015 Apr 23. Review.

19.

Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.

Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI.

J Clin Oncol. 2015 Mar 20;33(9):1053-9. doi: 10.1200/JCO.2014.58.3062. Epub 2015 Feb 17.

20.

The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.

Hershman DL, Tsui J, Meyer J, Glied S, Hillyer GC, Wright JD, Neugut AI.

J Natl Cancer Inst. 2014 Oct 27;106(11). pii: dju319. doi: 10.1093/jnci/dju319. Print 2014 Nov.

Supplemental Content

Support Center